TY - JOUR
T1 - Cellular senescence in age-related disorders
AU - Kaur, Japneet
AU - Farr, Joshua N.
N1 - Funding Information:
Dr. Farr is supported by National Institutes of Health (NIH) grants P01 AG062413 , R21 AG065868 , and K01 AR070241 , and both a High-Risk Pilot Award and a Career Development Award from the Mayo Clinic Robert and Arlene Kogod Center on Aging, as well as the Richard F. Emslander Career Development Award in Endocrinology. The authors apologize in advance that, due to space constraints, several original articles and reviews could not be included. All authors have read the journal's policy on conflicts of interest. The authors do not have a relevant conflict of interest. All authors have read the journal's authorship agreement. Conflicts of interest: Authors do not have a relevant financial conflict of interest.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12
Y1 - 2020/12
N2 - Much of the population is now faced with an enormous burden of age-associated chronic diseases. Recent discoveries in geroscience indicate that healthspan in model organisms such as mice can be manipulated by targeting cellular senescence, a hallmark mechanism of aging, defined as an irreversible proliferative arrest that occurs when cells experience oncogenic or other diverse forms of damage. Senescent cells and their proinflammatory secretome have emerged as contributors to age-related tissue dysfunction and morbidity. Cellular senescence has causal roles in mediating osteoporosis, frailty, cardiovascular diseases, osteoarthritis, pulmonary fibrosis, renal diseases, neurodegenerative diseases, hepatic steatosis, and metabolic dysfunction. Therapeutically targeting senescent cells in mice can prevent, delay, or alleviate each of these conditions. Therefore, senotherapeutic approaches, including senolytics and senomorphics, that either selectively eliminate senescent cells or interfere with their ability to promote tissue dysfunction, are gaining momentum as potential realistic strategies to abrogate human senescence to thereby compress morbidity and extend healthspan.
AB - Much of the population is now faced with an enormous burden of age-associated chronic diseases. Recent discoveries in geroscience indicate that healthspan in model organisms such as mice can be manipulated by targeting cellular senescence, a hallmark mechanism of aging, defined as an irreversible proliferative arrest that occurs when cells experience oncogenic or other diverse forms of damage. Senescent cells and their proinflammatory secretome have emerged as contributors to age-related tissue dysfunction and morbidity. Cellular senescence has causal roles in mediating osteoporosis, frailty, cardiovascular diseases, osteoarthritis, pulmonary fibrosis, renal diseases, neurodegenerative diseases, hepatic steatosis, and metabolic dysfunction. Therapeutically targeting senescent cells in mice can prevent, delay, or alleviate each of these conditions. Therefore, senotherapeutic approaches, including senolytics and senomorphics, that either selectively eliminate senescent cells or interfere with their ability to promote tissue dysfunction, are gaining momentum as potential realistic strategies to abrogate human senescence to thereby compress morbidity and extend healthspan.
UR - http://www.scopus.com/inward/record.url?scp=85087484517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087484517&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2020.06.007
DO - 10.1016/j.trsl.2020.06.007
M3 - Review article
C2 - 32569840
AN - SCOPUS:85087484517
SN - 1931-5244
VL - 226
SP - 96
EP - 104
JO - Translational Research
JF - Translational Research
ER -